See more : Twiik AB (publ) (TWIIK.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Novozymes A/S (NVZMY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Novozymes A/S, a leading company in the Chemicals – Specialty industry within the Basic Materials sector.
You may be interested
- Gores Guggenheim, Inc. (GGPIU) Income Statement Analysis – Financial Results
- The Now Corporation (NWPN) Income Statement Analysis – Financial Results
- TV Asahi Holdings Corporation (9409.T) Income Statement Analysis – Financial Results
- Xtreme Fighting Championships, Inc. (XFCI) Income Statement Analysis – Financial Results
- Pinewood Technologies Group PLC (PINE.L) Income Statement Analysis – Financial Results
Novozymes A/S (NVZMY)
About Novozymes A/S
Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company offers baking, beverages, dairy, starch, and protein solutions for the food and beverage industry; laundry, dishwashing, and professional cleaning solutions for the household care industry; agriculture solutions, including crop production, and animal health and nutrition solutions; bioyield and biocontrol solutions for crops; and grain and technical processing solutions, as well as bio energy solutions for liquefaction, saccharifaction, fermentation, fiber conversion, and biomass conversion. It also provides textile solutions, such as biopreparation, biopolishing, bleach clean-up, denim abrasion and finishing, and desizing solutions. In addition, the company offers solutions for pulp & paper, including fiber modification, bleach boosting, deposit control, starch modification, and deinking; leather solutions comprising acid bating, area expansion, bating, degreasing, soaking, and unhairing and liming; and water and waste management solutions, which consist of bioaugmentation, biogas, and sludge management. Further, it provides pharmaceutical solutions, including lipases, immobilized lipases, and proteases for biocatalysis, as well as rTrypsin for cell culture; and human health and protein solutions. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 17.90B | 17.55B | 14.95B | 14.01B | 14.37B | 14.39B | 14.53B | 14.14B | 14.00B | 12.46B | 11.75B | 11.23B | 10.51B | 9.72B | 8.45B | 8.15B | 7.44B | 6.80B | 6.28B | 6.02B | 5.80B | 5.64B |
| Cost of Revenue | 8.18B | 7.98B | 6.33B | 6.16B | 6.42B | 6.14B | 6.12B | 6.02B | 5.87B | 5.31B | 5.03B | 4.81B | 4.60B | 4.31B | 3.75B | 3.79B | 3.49B | 3.15B | 2.94B | 2.85B | 2.80B | 2.73B |
| Gross Profit | 9.72B | 9.58B | 8.62B | 7.85B | 7.95B | 8.26B | 8.41B | 8.13B | 8.13B | 7.15B | 6.72B | 6.42B | 5.91B | 5.41B | 4.70B | 4.36B | 3.95B | 3.66B | 3.35B | 3.18B | 3.00B | 2.91B |
| Gross Profit Ratio | 54.32% | 54.56% | 57.68% | 56.04% | 55.34% | 57.37% | 57.90% | 57.46% | 58.06% | 57.38% | 57.18% | 57.17% | 56.21% | 55.66% | 55.63% | 53.51% | 53.09% | 53.73% | 53.26% | 52.77% | 51.77% | 51.54% |
| Research & Development | 2.02B | 2.00B | 2.01B | 1.94B | 1.97B | 1.87B | 1.91B | 1.87B | 1.90B | 1.84B | 1.53B | 1.53B | 1.46B | 1.36B | 1.21B | 1.10B | 995.00M | 880.00M | 793.00M | 775.00M | 749.00M | 713.00M |
| General & Administrative | 959.00M | 952.00M | 859.00M | 739.00M | 838.00M | 792.00M | 831.00M | 810.00M | 876.00M | 857.00M | 824.00M | 808.00M | 778.00M | 762.00M | 751.00M | 745.00M | 675.00M | 650.00M | 632.00M | 595.00M | 587.00M | 575.00M |
| Selling & Marketing | 2.37B | 2.27B | 1.94B | 1.58B | 1.63B | 1.57B | 1.62B | 1.62B | 1.57B | 1.41B | 1.48B | 1.42B | 1.38B | 1.24B | 1.12B | 1.06B | 921.00M | 844.00M | 748.00M | 750.00M | 730.00M | 729.00M |
| SG&A | 3.32B | 3.22B | 2.80B | 2.32B | 2.47B | 2.36B | 2.45B | 2.43B | 2.45B | 2.26B | 2.30B | 2.23B | 2.15B | 2.00B | 1.87B | 1.81B | 1.60B | 1.49B | 1.38B | 1.35B | 1.32B | 1.30B |
| Other Expenses | 405.00M | -75.00M | -66.00M | -14.00M | -26.00M | -43.00M | -63.00M | -117.00M | -98.00M | -102.00M | -13.00M | 9.00M | -50.00M | -69.00M | -64.00M | -47.00M | -123.00M | -59.00M | -34.00M | -31.00M | -44.00M | -56.00M |
| Operating Expenses | 5.75B | 5.15B | 4.74B | 4.24B | 4.41B | 4.19B | 4.30B | 4.18B | 4.25B | 4.00B | 3.82B | 3.68B | 3.57B | 3.30B | 3.01B | 2.86B | 2.47B | 2.32B | 2.14B | 2.09B | 2.02B | 1.96B |
| Cost & Expenses | 13.92B | 13.13B | 11.07B | 10.40B | 10.83B | 10.32B | 10.42B | 10.20B | 10.12B | 9.31B | 8.85B | 8.49B | 8.17B | 7.61B | 6.76B | 6.64B | 5.96B | 5.46B | 5.08B | 4.93B | 4.82B | 4.70B |
| Interest Income | 24.00M | 18.00M | 18.00M | 10.00M | 90.00M | 10.00M | 7.00M | 5.00M | 4.00M | 9.00M | 5.00M | 13.00M | 208.00M | 113.00M | 153.00M | 263.00M | 130.00M | 134.00M | 76.00M | 89.00M | 223.00M | 131.00M |
| Interest Expense | 173.00M | 102.00M | 102.00M | 63.00M | 86.00M | 13.00M | 27.00M | 31.00M | 31.00M | 58.00M | 66.00M | 74.00M | 133.00M | 107.00M | 220.00M | 348.00M | 226.00M | 256.00M | 132.00M | 98.00M | 190.00M | 178.00M |
| Depreciation & Amortization | 1.39B | 1.46B | 1.37B | 1.23B | 1.17B | 1.01B | 1.04B | 974.00M | 953.00M | 866.00M | 738.00M | 703.00M | 208.00M | 113.00M | 564.00M | 556.00M | 490.00M | 469.00M | 462.00M | 519.00M | 523.00M | 532.00M |
| EBITDA | 5.47B | 6.12B | 5.20B | 4.85B | 5.07B | 5.04B | 5.19B | 4.89B | 4.77B | 4.20B | 3.56B | 3.36B | 2.55B | 2.23B | 2.41B | 2.32B | 2.10B | 1.94B | 1.74B | 1.67B | 1.73B | 1.61B |
| EBITDA Ratio | 30.57% | 34.60% | 34.76% | 34.26% | 32.84% | 34.60% | 35.74% | 34.36% | 34.08% | 31.73% | 29.86% | 29.92% | 24.24% | 22.93% | 28.47% | 28.52% | 28.25% | 10.92% | 27.77% | 28.19% | 29.78% | 28.54% |
| Operating Income | 3.98B | 4.63B | 4.01B | 3.65B | 4.04B | 4.07B | 4.05B | 3.95B | 3.88B | 3.38B | 2.90B | 2.75B | 2.34B | 2.12B | 1.69B | 1.50B | 1.48B | 1.34B | 1.21B | 1.09B | 982.00M | 947.00M |
| Operating Income Ratio | 22.21% | 26.37% | 26.80% | 26.06% | 28.10% | 28.28% | 27.85% | 27.90% | 27.74% | 27.16% | 24.70% | 24.43% | 22.26% | 21.77% | 19.98% | 18.46% | 19.91% | 19.70% | 19.20% | 18.09% | 16.92% | 16.78% |
| Total Other Income/Expenses | -67.00M | -73.00M | -83.00M | -131.00M | -240.00M | -134.00M | -171.00M | -65.00M | -263.00M | -105.00M | -142.00M | -161.00M | 75.00M | 6.00M | -67.00M | -85.00M | -96.00M | -122.00M | -56.00M | -33.00M | 33.00M | -47.00M |
| Income Before Tax | 3.91B | 4.56B | 3.92B | 3.52B | 3.80B | 3.94B | 3.88B | 3.88B | 3.62B | 3.28B | 2.76B | 2.58B | 2.42B | 2.12B | 1.62B | 1.42B | 1.39B | 18.00M | 1.15B | 1.08B | 1.02B | 900.00M |
| Income Before Tax Ratio | 21.84% | 25.96% | 26.25% | 25.13% | 26.43% | 27.35% | 26.67% | 27.44% | 25.86% | 26.32% | 23.49% | 23.00% | 22.98% | 21.83% | 19.19% | 17.42% | 18.62% | 0.26% | 18.31% | 17.94% | 17.49% | 15.95% |
| Income Tax Expense | 870.00M | 870.00M | 779.00M | 695.00M | 644.00M | 709.00M | 756.00M | 831.00M | 796.00M | 754.00M | 558.00M | 568.00M | 587.00M | 509.00M | 427.00M | 357.00M | 343.00M | -307.00M | 289.00M | 288.00M | 280.00M | 253.00M |
| Net Income | 3.02B | 3.68B | 3.15B | 2.83B | 3.15B | 3.23B | 3.12B | 3.05B | 2.82B | 2.53B | 2.20B | 2.02B | 1.83B | 1.61B | 1.19B | 1.06B | 1.04B | 911.00M | 861.00M | 793.00M | 735.00M | 647.00M |
| Net Income Ratio | 16.89% | 20.94% | 21.04% | 20.16% | 21.94% | 22.42% | 21.46% | 21.57% | 20.16% | 20.27% | 18.73% | 17.94% | 17.39% | 16.60% | 14.13% | 13.04% | 14.01% | 13.39% | 13.71% | 13.16% | 12.67% | 11.47% |
| EPS | 10.88 | 13.29 | 11.32 | 10.07 | 11.06 | 11.11 | 10.56 | 10.15 | 9.23 | 8.10 | 7.01 | 6.42 | 5.80 | 5.15 | 3.85 | 3.43 | 3.37 | 2.90 | 2.63 | 2.32 | 2.09 | 1.79 |
| EPS Diluted | 10.88 | 13.19 | 11.23 | 10.02 | 11.01 | 11.03 | 10.49 | 10.06 | 9.12 | 8.02 | 6.93 | 6.33 | 5.71 | 5.05 | 3.79 | 3.37 | 3.28 | 2.82 | 2.57 | 2.27 | 2.07 | 1.78 |
| Weighted Avg Shares Out | 277.94M | 276.64M | 277.92M | 280.43M | 285.11M | 290.42M | 295.34M | 300.47M | 306.00M | 311.90M | 313.76M | 313.98M | 315.16M | 313.18M | 310.27M | 309.35M | 309.57M | 314.37M | 327.31M | 341.38M | 352.30M | 361.68M |
| Weighted Avg Shares Out (Dil) | 277.87M | 278.73M | 280.23M | 282.02M | 286.55M | 292.36M | 297.20M | 303.12M | 309.37M | 315.08M | 317.41M | 318.28M | 319.96M | 319.38M | 315.36M | 315.01M | 318.12M | 322.52M | 335.34M | 349.25M | 354.33M | 362.80M |
ESI or NVZMY: Which Is the Better Value Stock Right Now?
Investors with an interest in Chemical - Specialty stocks have likely encountered both Element Solutions (ESI) and Novozymes A/S (NVZMY). But which of these two companies is the best option for those looking for undervalued stocks?
Novozymes: Close To Being A Buy Again
Novozymes' stock is declining for almost two years and has lost almost 50% of its previous value. The company reported mediocre half-year results for fiscal 2023. But Novozymes has a wide economic moat around its business, making the company a...
Novozymes announce the Executive Leadership Team and organizational structure for the future combined company of Novozymes and Chr. Hansen
October 10, 2023 Please see attachment. Contact information Investor Relations Anders Mohr Christensen+45 2515 2364 [email protected] Press Relations Sanne Seyer-Hansen+45 6038 6207 [email protected] Attachment 2023_Novozymes announce the Executive Leadership Team and organizational structure
Executive Leadership Team and organizational structure announced for the future combined company of Novozymes and Chr. Hansen
Read the full announcement in PDF Attachment 2023_57_Executive_Leadership_Team
International Wide-Moat Stocks On Sale - The October 2023 Heat Map
Our 3-step process focuses on wide-moat stocks (as per Morningstar's rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may be worth your...
Novozymes Named EPA Safer Choice Partner of the Year for Third Year in a Row
World's Leading Biotech Powerhouse Recognized for Providing and Advocating for Ingredients that Create Safer Detergents FRANKLINTON, N.C. , Oct. 3, 2023 /PRNewswire/ -- Novozymes was named a 2023 Safer Choice® Partner of the Year by the U.S. Environmental Protection Agency (EPA)...
Novozymes launches new biosolution to redefine the plant-based meat experience by enhancing texture and encouraging more consumers to choose plant-based alternatives
Novozymes is excited to offer Vertera® ProBite as a game-changing solution to the plant-based meat industry, opening up new possibilities to create today's and tomorrow's plant-based meat products with advanced texture and consumer-friendly labels. The new product is a part...
PPG or NVZMY: Which Is the Better Value Stock Right Now?
Investors with an interest in Chemical - Specialty stocks have likely encountered both PPG Industries (PPG) and Novozymes A/S (NVZMY). But which of these two stocks presents investors with the better value opportunity right now?
Update on the combination of Novozymes and Chr. Hansen: Chinese merger approval granted, supporting the path to completion
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY (IN WHOLE OR IN PART), IN OR INTO THE UNITED STATES, CANADA, SOUTH AFRICA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION WHERE SUCH ACTION WOULD BE UNLAWFUL.
Update on the combination of Novozymes and Chr. Hansen: Chinese merger approval granted, supporting the path to completion
Please read the announcement in PDF Attachment 2023_Chinese_merger_approval_granted
Source: https://incomestatements.info
Category: Stock Reports